An ASF funded research study was published in BioRXiv and the Journal of Clinical Investigation. See the press release below for more information and the outcomes of the study. UNC School of Medicine researchers led by Ben Philpot, PhD, and Bin Gu, PhD, found that […]
Read more
Neuren Pharmaceutical’s candidate NNZ-2591 has shown positive effects in a mouse model of Angelman syndrome, treating all symptoms of the disease, the company announced. These results were used to submit an Orphan Drug application to the U.S. Food and Drug Administration (FDA). Angelman syndrome is a genetic neurological […]
Read more
At the 2019 ASF Scientific Symposium and Family Conference in Louisville, KY, the Angelman Syndrome Foundation recognized four people with special awards at the Family Conference Welcome Reception. The board and staff of the Angelman Syndrome Foundation, as well as […]
Read more
The Angelman Syndrome Foundation (ASF) has announced that Dr. Elizabeth Jalazo, a pediatrician at the University of North Carolina in Chapel Hill, will take on the new position of Director of Clinical Integration for the ASF. In her role as […]
Read moreImportant work coming out of the ASF Clinic Network at the University of North Carolina at Chapel Hill. Did you know that anxiety concerns are reported in 40% of people with AS? Characterizing that anxiety is critically important to design […]
Read more
Your ASF donations hard at work at UNC and Erasmus Medical Center in the Netherlands. This pivotal study demonstrated that UBE3A is most critical in the developing brain and plays a less vital role later on in life. This is […]
Read moreAnxiety in Angelman Syndrome Important work coming out of the ASF Clinic Network at the University of North Carolina at Chapel Hill. Did you know that anxiety concerns are reported in 40% of people with AS? Characterizing that anxiety is […]
Read more
See the following announcement from May 16, 2019. Also, see a Q&A on this collaboration for more details. Dear Angelman Syndrome Community, We, Roche, Biogen and Ionis, are amongst several companies working towards finding potential treatments for Angelman Syndrome (AS). […]
Read more
